Sodium glucose co‐transporter 2 (SGLT2) is an emerging target for the treatment of type 2 diabetes mellitus (DM2). Here, the synthesis and preliminary biological evaluation of a series of potent, selectiveSGLT2inhibitors, derived from a rigid spiro C‐arylglucoside scaffold, is described.